SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Monogram Biosciences, Inc. (Nasdaq:MGRM) today announced that it received a staff deficiency letter from the Nasdaq Stock Market (“Nasdaq”), dated December 3, 2008, indicating that, for the last 10 consecutive business days, the market value of Monogram’s listed securities has been below the minimum $50 million requirement for continued inclusion on the Nasdaq Global Market under Marketplace Rule 4450(b)(1)(A). The letter further indicated that Monogram is not in compliance with an alternative requirement for continued listing under Marketplace Rule 4450(b)(1)(B), which requires total assets and total revenue of $50 million each for the most recently completed fiscal year or two of the last three most recently completed fiscal years.
